30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Axovant Gene Therapies Ltd (AXGT)

Track

Stock chart
Ticker: AXGT Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Cheruvu Pavan
Chief Executive Officer
1 purchase — total 248,180 USD
Buy 23 Mar 2021
Value US$3,746,057.74 | Price 318.60 | Shares 10,237
Buy 24 Nov 2020
Value US$3,660,196.39 | Price 138.78 | Shares 58,596
Buy 8 Jul 2020
Value US$102,637.50 | Price 2.74 | Shares 37,500
Buy 8 Jul 2020
Value US$27,290.00 | Price 2.73 | Shares 10,000
Buy 16 Mar 2020
Value US$17,844.00 | Price 1.78 | Shares 10,000
Buy 24 Feb 2020
Value US$19,999,998.75 | Price 3.75 | Shares 5,333,333
Buy 14 Jun 2019
Value US$17,595.44 | Price 5.22 | Shares 3,370
Buy 14 Jun 2019
Value US$39,075.00 | Price 5.21 | Shares 7,500
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Mar 2019
Value US$10,000,000.50 | Price 1.50 | Shares 6,666,667
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 18 Dec 2018
Value US$10,000,000.00 | Price 1.00 | Shares 10,000,000
Buy 9 Aug 2018
Value US$51,750.00 | Price 2.07 | Shares 25,000
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 5 Jun 2018
Value US$24,999,999.50 | Price 1.75 | Shares 14,285,714
Buy 27 Feb 2018
Value US$37,425.00 | Price 1.50 | Shares 25,000
Buy 17 Apr 2017
Value US$10,000,012.50 | Price 18.54 | Shares 539,375
Buy 17 Apr 2017
Value US$999,991.98 | Price 18.54 | Shares 53,937
Buy 17 Apr 2017
Value US$999,991.98 | Price 18.54 | Shares 53,937
Buy 10 Mar 2016
Value US$25,622.00 | Price 11.14 | Shares 2,300
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-03-24 2021-03-23 B Purchase
Cheruvu Pavan

Chief Executive Officer

Executive Director
10,237 +38.6%
318.60
US$3,746,058 		10,237 +38.6% 318.60 US$3,746,058
2020-11-25 2020-11-24 B Purchase
3.4
Pande Atul
Non-Executive Director
58,596 -13.2%
138.78
US$3,660,196 		58,596 -13.2% 138.78 US$3,660,196
2020-07-10 2020-07-08 B Purchase
Cheruvu Pavan

Principal Executive Officer

Executive Director
37,969 +45.7%
194.92
US$1,331,093 		37,969 +45.7% 194.92 US$1,331,093
2020-07-10 2020-07-08 B Purchase
3.4
Pande Atul
Non-Executive Director
10,000 +74.8%
2.73
US$27,290 		10,000 +74.8% 2.73 US$27,290
2020-03-18 2020-03-16 B Purchase
3.4
Pande Atul
Non-Executive Director
10,000 +296.7%
1.78
US$17,844 		10,000 +296.7% 1.78 US$17,844
2020-02-27 2020-02-24 B Purchase
1.9
Roivant Sciences Ltd.
Large shareholder
5,333,333 +40.3%
3.75
US$19,999,999 		5,333,333 +40.3% 3.75 US$19,999,999
2019-06-17 2019-06-14 B Purchase
3.4
Pande Atul
3,370 +inf%
5.22
US$17,595 		3,370 +inf% 5.22 US$17,595
2019-06-17 2019-06-14 B Purchase
Cheruvu Pavan

Chief Executive Officer

Executive Director
7,500 +inf%
5.21
US$39,075 		7,500 +inf% 5.21 US$39,075
2019-03-19 2019-03-18 B Purchase
1.9
Roivant Sciences Ltd.
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
1.5
Machado Patrick
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
Dexxon Holdings Ltd.
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
QVT Associates GP LLC
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
3.2
SVF Investments (UK) Ltd
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
2.5
Lo Andrew
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
2.0
VIKING GLOBAL PERFORMANCE LLC
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2018-12-20 2018-12-18 B Purchase Roivant Sciences Ltd. Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase SVF Investments (UK) Ltd Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase VIKING GLOBAL PERFORMANCE LLC Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase Dexxon Holdings Ltd. Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase VIKING GLOBAL INVESTORS LP Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase Lo Andrew Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase Machado Patrick Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase QVT Associates GP LLC Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-08-13 2018-08-09 B Purchase Bickerstaff George Non-Executive Director
25,000 +100.0%
2.07
US$51,750 		25,000 +100.0% 2.07 US$51,750
2018-06-07 2018-06-05 B Purchase SVF Investments (UK) Ltd Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Roivant Sciences Ltd. Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Dexxon Holdings Ltd. Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Lo Andrew Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase VIKING GLOBAL PERFORMANCE LLC Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase QVT Associates GP LLC Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Machado Patrick Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase VIKING GLOBAL INVESTORS LP Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-03-01 2018-02-27 B Purchase Bickerstaff George
25,000 +inf%
1.50
US$37,425 		25,000 +inf% 1.50 US$37,425
2017-04-19 2017-04-17 B Purchase Hung David

Principal Executive Officer

Executive Director
539,375 +inf%
18.54
US$10,000,012 		539,375 +inf% 18.54 US$10,000,012
2017-04-19 2017-04-17 B Purchase FALBERG KATHRYN E
53,937 +inf%
18.54
US$999,992 		53,937 +inf% 18.54 US$999,992
2017-04-19 2017-04-17 B Purchase VERNON W ANTHONY
53,937 +inf%
18.54
US$999,992 		53,937 +inf% 18.54 US$999,992
2016-03-14 2016-03-10 B Purchase Altmeyer Mark

Pres&Chief Commercial Officer

Officer
2,300 +inf%
11.14
US$25,622 		2,300 +inf% 11.14 US$25,622
Explore more

More insider trading research around Axovant Gene Therapies Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America